Provided by Tiger Fintech (Singapore) Pte. Ltd.

XILIO THERAPEUTICS, INC.

0.8150
+0.06348.44%
Volume:299.57K
Turnover:235.62K
Market Cap:42.20M
PE:-0.75
High:0.8200
Open:0.7352
Low:0.7350
Close:0.7516
Loading ...

Company Profile

Company Name:
XILIO THERAPEUTICS, INC.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
64
Office Location:
828 Winter Street,Suite 300,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Daniel S. Lynch
Chairman of the Board
Rene Russo
President and Chief Executive Officer, Director
Christina Rossi
Director
Daniel Curran
Director
Michael Ross
Director
Paul J. Clancy
Director
Rachel Humphrey
Director
Sara M. Bonstein
Director

Shareholders

Name
Position
Rene Russo
President and Chief Executive Officer, Director
Salvatore Giovine
Chief Financial Officer
Martin Huber
President of R&D and Chief Medical Officer